Search Results - "Thepot, S."

Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia by Tailler, M, Senovilla, L, Lainey, E, Thépot, S, Métivier, D, Sébert, M, Baud, V, Billot, K, Fenaux, P, Galluzzi, L, Boehrer, S, Kroemer, G, Kepp, O

“…Despite recent progress in the treatment of acute myeloid leukemia (AML), the prognosis of this rather heterogeneous disease remains poor and novel…”
Get full text

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine by Itzykson, R, Thépot, S, Eclache, V, Quesnel, B, Dreyfus, F, Beyne-Rauzy, O, Turlure, P, Vey, N, Recher, C, Boehrer, S, Gardin, C, Adès, L, Fenaux, P

Get full text

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation by Thepot, S, Zhou, J, Perrot, A, Robin, M, Xhaard, A, de Latour, R P, Ades, L, Ribaud, P, Petropoulou, A D, Porcher, R, Socié, G

“…Incidence on relapse and nonrelapse mortality (NRM) of chronic graft-versus-host disease (GVHD), per National Institutes of Health (NIH) criteria, is not well…”
Get full text

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? by Itzykson, R, Thépot, S, Beyne-Rauzy, O, Ame, S, Isnard, F, Dreyfus, F, Salanoubat, C, Taksin, A.L, Chelgoum, Y, Berthon, C, Malfuson, J.V, Legros, L, Vey, N, Turlure, P, Gardin, C, Boehrer, S, Ades, L, Fenaux, P

“…Abstract We studied a retrospective cohort of 282 higher-risk MDS treated with azacitidine, including 32 patients who concomitantly received an ESA for a…”
Get full text

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome by Boehrer, S, Adès, L, Tajeddine, N, Hofmann, W K, Kriener, S, Bug, G, Ottmann, O G, Ruthardt, M, Galluzzi, L, Fouassier, C, Tailler, M, Olaussen, K A, Gardin, C, Eclache, V, de Botton, S, Thepot, S, Fenaux, P, Kroemer, G

“…The molecular mechanisms responsible for the evolution from the preleukemic entities of low-risk myelodysplastic syndrome (MDS) to the less favorable forms of…”
Get full text

Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents by Park, S, Hamel, J.F, Toma, A, Kelaidi, C, Thepot, S, Campelo Diez, M, Santini, V, Sekeres, M, Balleari, E, Kaivers, J, Goetze, K, Beyne-Rauzy, O, Stamatoullas, A, Kotsianidis, I, Komrokji, R, Steensma, D, Germing, U, Sanz, G, Dreyfus, F, Fenaux, P

Get full text

Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence by López Cadenas, F, Xicoy, B, Sánchez, J, Fenaux, P, Hernández Rivas, J.Á, Amigo, M.L, Coll, R, Lumbreras, E, Slama, B, Bernal, T, De Paz, R, Platzbecker, U, Giagounidis, A, Nomdedeu, B, Thepot, S, Sanz, G, Arrizabalaga, B, Bargay, J, Del Cañizo Fernández-Roldán, M.C, Díez-Campelo, M

Get full text

P-284 Impact of cytogenetics and cytogeneticresponse on outcome in MDS treated with azacitidine (AZA) by Sebert, M, Vidal, V, Eclache, V, Thepot, S, Itzykson, R, Braun, T, Gardin, C, Fenaux, P, Ades, L

Get full text

O-017 A Phase I/II trial of erlotinib (ERLO) in higher-risk MDS after azacitidine (AZA) failure by Thepot, S, Boehrer, S, Prebet, T, Beyne-Rauzy, O, Wattel, E, Delaunay, J, Raffoux, E, Schmidt, A.L, Wickenhauser, S, Dreyfus, F, Fenaux, P, Adès, L

Get full text

O-010 Prognostic factors of response to azacitidine (AZA) in low-risk MDS resistant to erythroid stimulating agents (ESA). The GFM Azaepo 08 study by Gardin, C, Thepot, S, Beyne-Rauzy, O, Benabdelali, R, Prebet, T, Park, S, Stamatoulas, A, Guerci-Bresler, A, Cheze, S, Tertian, G, Choufi, B, Legros, L, Bastie, J.N, Delaunay, J, Chaury, M.P, Wattel, E, Dreyfus, F, Preudhomme, C, Vey, N, Fenaux, P

Get full text

165 Synergistic effects on apoptosis in higher risk MDS by combining azacitidine (AZA) and the EGFR-tyrosine kinase inhibitor erlotinib by Elodie, L, Sebert, M, Thepot, S, Tailler, M, Bouteloup, C, Leroy, C, Ades, L, Fenaux, P, Boehrer, S

Get full text

188 The EGFR-inhibitor erlotinib sensitizes MDS derived cells to chemotherapeutic agents by increasing their intracellular retention via modulation of ABC-transporters by Sebert, M, Elodie, L, Thepot, S, Tailler, M, Leroy, C, Bouteloup, C, Ades, L, Gardin, C, Fenaux, P, Boehrer, S

Get full text

105 Outcome of high risk myelodysplastic syndrome after azacytidine failure by Prebet, T, Gore, S.D, Esterni, B, Itzikson, R, Thepot, S, Beach, C.L, Fenaux, P, Vey, N

Get full text

189 Hypomethylating agents induce apoptosis and cell cycle arrest with a concomitant activation of p53-dependent signalling pathways and Foxo3a activation by Thepot, S, Lainey, E, Sebert, M, Tailler, M, Leroy, C, Bouteloup, C, Ades, L, Gardin, C, Fenaux, P, Kroemer, G, Boehrer, S

Get full text

172 Azacytidine in relapsed MDS and AML after allogeneic stem cell transplantation: Results of the French ATU Program by Guièze, R, Jouinot, A, Itzykson, R, Thepot, S, Guillaume, T, Coiteux, V, Wittnebel, S, de Botton, S, Dartigeas, C, Sirvent, A, Turlure, P, Bouscary, D, Robin, M, Vernant, J.-P, Sutton, L, Dreyfus, F, Bay, J.-O, Adès, L, Fenaux, P

Get full text

174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)? by Itzykson, R, Thepot, S, Beyne-Rauzy, O, Ame, S, Isnard, F, Salanoubat, C, Taksin, A.-L, Chelgoum, Y, Quesnel, B, Malfuson, J.-V, Legros, L, Vey, N, Turlure, P, Gardin, C, Boehrer, S, Ades, L, Fenaux, P

Get full text

106 Treatment of advanced CMML by azacitidine (AZA) in a compassionate program. The GFM experience in 38 patients (pts) by Wolfromm, A, Dreyfus, F, Vey, N, Delaunay, J, Stamatoullas, A, Banos, A, Marfaing-Koka, A, De Botton, S, Bordessoule, D, Legros, L, Rauzy, O. Beynes, Gyan, E, Makhoul, P. Cony, Thepot, S, Itzykson, R, Fenaux, P, Ades, L

Get full text

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction by Ramos, F, Thépot, S, Pleyer, L, Maurillo, L, Itzykson, R, Bargay, J, Stauder, R, Venditti, A, Seegers, V, Martínez-Robles, V, Burgstaller, S, Récher, C, Debén, G, Gaidano, G, Gardin, C, Musto, P, Greil, R, Sánchez-Guijo, F, Fenaux, P

“…Highlights • European ALMA score (E-ALMA) takes into consideration ECOG, WBC and cytogenetics. • It may be used in unfit WHO-defined AML patients treated…”
Get full text

P126 Treatment of progression of myeloproliferative neoplasm (MPN) to MDS/AML by azacytidine (AZA): a report on 44 patients (pts) by Thepot, S, Itzykson, R, Raffoux, E, Recher, C, Quesnel, B, Dreyfus, F, Cluzeau, T, Chait, Y, Cassinat, B, Zerhouni, C, Roussel, M, Kiladjian, J, Gardin, C, Fenaux, P, Ades, L

Get full text

185 SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA AFTER CHRONIC MYELOMONOCYTIC LEUKEMIA: AN UNCOMMON CASE REPORT OF CLONAL EVOLUTION by Corby, A, Geneviève, F, Baranger-Papot, L, Bouvier, A, Hunault-Berger, M, Ifrah, N, Thépot, S

Get full text